TipRanks
In the investing game, its not only about what you buy; its about when you buy it. One of the most common pieces of advice thrown around the Street, buy low is touted as a tried-and-true tactic.Sure, the strategy seems simple. Stock prices naturally fluctuate on the basis of several factors like earnings results and the macro environment, amongst others, with investors trying to time the market and determine when stocks have hit a bottom. In practice, however, executing on this strategy is no easy task.On top of this, given the volatility that has ruled the markets over the last few weeks, how are investors supposed to gauge when a name is flirting with a bottom? Thats where the Wall Street pros come in.These expert stock pickers have identified three compelling tickers whose current share prices land close to their 52-week lows. Noting that each is set to take back off on an upward trajectory, the analysts see an attractive entry point. Using TipRanks database, we found out that the analyst consensus has rated all three a Strong Buy, with major upside potential also on tap.Progenity (PROG)Offering clear and actionable genetic results, Progenity specializes in providing testing services. The company started trading on Nasdaq in June and saw its shares tumbling 44% since then. With shares changing hands for $8.11, several members of the Street recommend pulling the trigger before it heats up.Piper Sandler analyst Steven Mah points out that even against the backdrop of COVID-19, PROG managed to deliver with its Q2 2020 performance. We are encouraged by the recovery in late Q2 2020 with 75,000 accessioned tests (~79,000 in Q1 2020), driven by noninvasive prenatal testing (NIPT) and carrier screening, the analyst noted. Expounding on this, Mah stated, Progenity did not provide guidance, but June test volumes of ~28,000 were strong (Q1 2020 monthly average was ~26,000) which we believe showcases the durability of its reproductive tests and the success that Progenity has in co-marketing and attaching carrier screening to the more essential NIPT. Of note, despite the pandemic disruptions, Progenity was able to maintain its leading pre-COVID test turnaround times.Additionally, health insurer Aetna is temporarily extending coverage of average-risk NIPT until year-end as a result of the pandemic, with the American College of Obstetricians and Gynecologists (ACOG) also expected to endorse average-risk in the future given its clinical utility, in Mahs opinion.Reflecting another positive, the fourth generation NIPT (single-molecule counting assay) test was able to measure fetal fraction, a key milestone according to Mah, and will continue to be developed into 2021. As the technology could potentially be applied to DNA, RNA, epigenetic markers and proteins for additional clinical applications such as oncology, the analyst is looking forward to the completion of the preeclampsia verification in Q4 2020 and a possible 2H21 launch. We believe preeclampsia (~2.3 billion serviceable market) is a major differentiator for Progenity, allowing them to cross-sell across the full-continuum of reproductive testing, the analyst added.If that wasnt enough, PROG signed its first GI Precision Medicine partnership agreement with a top-20 Pharma company in August. The Oral Biotherapeutic Delivery System (OBDS), an ingestible drug and device combination designed to precisely deliver biologics systemically through a needle-free liquid jet injection into the submucosal tissues of the small intestine, is set to be utilized as part of the collaboration. Mah commented, We believe Progenity can sign additional Pharma deals and look forward to the newsflow coming out on this front.To sum it all up, Mah said, We believe Progenity shares are undervalued given the robust recovery in the core testing business and multiple upcoming growth catalysts.To this end, Mah rates PROG an Overweight (i.e. Buy) along with a $17 price target. Should his thesis play out, a twelve-month gain of 105% could potentially be in the cards. (To watch Mahs track record, click here)Are other analysts in agreement? They are. Only Buy ratings, 4, in fact, have been issued in the last three months. Therefore, the message is clear: PROG is a Strong Buy. Given the $13.33 average price target, shares could climb 60% higher in the next year. (See PROG stock analysis on TipRanks)Tactile Systems Technology (TCMD)Developing at-home therapy devices, Tactile Systems Technology wants to provide new treatments for lymphedema, which occurs when the lymphatic system is impaired, disrupting normal transport of fluid within the body, and chronic venous insufficiency. Down 52% year-to-date, its $32.67 share price lands close to its $29.47 52-week low. Thus, with business trends improving, the Street is pounding the table.Writing for Canaccord, analyst Cecilia Furlong acknowledges that the pandemic has hampered the company, with COVID-19 weighing on both volumes and sales. In the second half of March, volumes were down 50% compared to the first half of the month, and TCMDs patient volumes in April and May remained challenged. That being said, trends started to improve at the end of May.Going forward, given the vast majority of TCMDs clinician customers practice in outpatient or office-based settings, we remain positive on TCMDs ability to demonstrate better insulation against COVID impacts and likely experience a greater bounce-back relative to overall med-tech volume trends, with TCMD further benefitting from its expanding using of technology to remotely engage with clinicians and support patients, Furlong explained.The analyst added, Furthermore, recent trends among some providers to prescribe Flexitouch (an advanced intermittent pneumatic compression device to self-manage lymphedema and nonhealing venous leg ulcers) earlier along the therapy process, as a means to reduce in-person contact, could provide upside near term, as well as potentially transition to a longer-term tailwind.On top of this, Furlong is also optimistic about new CEO Dan Reuvers and the reprioritization of the companys investment and market development efforts. TCMD will shift focus away from its acquired Airwear product line, with it redirecting investments toward its Flexitouch and Entre (a pneumatic compression device used to assist in the home management of chronic swelling and venous ulcers associated with lymphedema and chronic venous insufficiency) products.Given significant under-penetration in the lymphedema/phlebolymphedema market targeted by Flexitouch alongside the large patient population with limited treatment options today targeted by the firms Head & Neck platform, we view the combination of education and clinical data as key to further developing and penetrating these markets... Going forward, we expect management to continue to compile a broad base of clinical data to support reimbursement and drive broad adoption, Furlong commented.All of this prompted Furlong to keep a Buy rating and $62 price target on the stock. This target conveys her confidence in TCMDs ability to soar 90% in the next year. (To watch Furlongs track record, click here)In general, other analysts are on the same page. With 3 Buy ratings and 1 Hold, the word on the Street is that TCMD is a Strong Buy. The $62.33 average price target brings the upside potential to 91%. (See TCMD stock analysis on TipRanks)uniQure N.V. (QURE)Last but not least we have uniQure, which delivers curative gene therapies that could potentially transform the lives of patients. Even though shares have fallen 44% year-to-date to $40, not much higher than its 52-week low of $36.20, multiple analysts still have high hopes.Representing SVB Leerink, 5-star analyst Joseph Schwartz acknowledges that shares struggled after news broke of its collaboration and licensing agreement with CSL Behring for AMT-061, QUREs gene therapy for Hemophilia B, he argues the shareholder base turnover is likely now complete as investors and QURE shift focus to next-in-line AMT-130, its AAV5 gene therapy for Huntingtons Disease (HD).Schwartz further added, With the M&A premium now out of the stock, we see the QUREs current level as an attractive buying opportunity for those investors interested in the companys up and coming CNS gene therapies, internal manufacturing, and robust intellectual property and knowhow.Looking more closely at the agreement with CSL Behring, QURE will be tasked with the completion of the pivotal Phase 3 HOPE-B trial as well as the manufacturing process validation and manufacturing supply of AMT-061.According to management, 26-week Factor IX (FIX) data from all 54 patients enrolled in the trial remains on track, and topline data from the pivotal trial is still slated to read out by YE20. It should be mentioned that in a Phase 2b dose-confirmation study, QURE reported 41% FIX activity out to one year. Additionally, Schwartz points out that with HOPE-B progressing as planned, QURE has continued its manufacturing process validation work ahead of the anticipated BLA/MAA submissions in the U.S. and EU in 2021.On top of this, as part of the deal, QURE is eligible to receive more than $2 billion including a $450 million upfront cash payment, $1.6 billion in regulatory and commercial milestones and double-digit royalties ranging up to the low-twenties percentage of net product sales.With a strengthened cash position, QURE is well funded to rapidly advance CNS assets including AMT-130 (AAV5 gene therapy for Huntingtons Disease (HD)) and AMT-150 (AAV gene therapy for Spinocerebellar Ataxia Type 3/SCA3)...We continue to believe that as QUREs CNS pipeline assets mature, the company could once again be an attractive partner to larger biopharma companies that have recently acquired many publicly traded gene therapy platforms with substantial manufacturing capabilities, Schwartz noted.Everything that QURE has going for it convinced Schwartz to reiterate an Outperform (i.e. Buy) rating. Along with the call, he attached a $67 price target, suggesting 68% upside potential from current levels. (To watch Schwartzs track record, click here)What does the rest of the Street have to say? 9 Buys and 3 Holds have been issued in the last three months, so the consensus rating is a Strong Buy. In addition, the $69.89 average price target indicates 75% upside potential. (See QURE stock analysis on TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- Types of Blindness, Causes, and Their Treatment - Healthline - March 28th, 2025
- Types of blindness: Partial, total, congenital, and more - March 28th, 2025
- International collaborations helping understand the physical activity levels and well-being of children with visual impairment - Murdoch University - March 28th, 2025
- Revel in the Rainbow: Color-Blindness-Correcting Glasses Debut at Wooden Shoe Festival - Portland Monthly - March 28th, 2025
- Prevent Blindness Declares April as Women's Eye Health and Safety Month, Providing Free Educational Resources to the Public and Professionals - PR Web - March 28th, 2025
- Partial blindness hasn't stopped Oklahoma State's Stailee Heard from leading the Cowgirls into NCAAs - The Washington Post - March 28th, 2025
- Nine out of ten cases of blindness caused by glaucoma could be prevented through annual check-ups - Euro Weekly News - March 28th, 2025
- The silent sight thief: The devastating effects of glaucoma on mental health and quality of life - News24 - March 28th, 2025
- Rosie O'Donnell Celebrates Her 63rd Birthday After Move to Ireland as She Slams 'Willful Blindness' in Trump Administration - AOL - March 28th, 2025
- Partial blindness hasn't stopped Oklahoma State's Stailee Heard from leading the Cowgirls into NCAAs - Eagle-Tribune - March 28th, 2025
- The Longevity Wake-Up Call And The Blindness Of Leadership To It - Forbes - February 24th, 2025
- Album Review: Blindness // The Murder Capital - The Indiependent - February 24th, 2025
- The Murder Capital - Blindness - Northern Transmissions - February 24th, 2025
- The Murder Capital: Blindness review - independent pop | Indie - The Line of Best Fit - February 24th, 2025
- Prevent Blindness Kicks Off Second Annual "Retinopathy of Prematurity (ROP) Awareness Week," Feb. 24- March 2, 2025, as Part of its ROP... - February 24th, 2025
- Prevent Blindness Kicks Off Second Annual Retinopathy of Prematurity Awareness Week - Vision Monday - February 24th, 2025
- Gene therapy for rare childhood blindness shows lasting vision gains - R&D World - February 24th, 2025
- The Murder Capital's Blindness: A Voice of Significance in an Era Craving Authentic Discourse - Indie Is Not A Genre - February 24th, 2025
- Albums Of The Week: The Murder Capital | Blindness - Tinnitist - February 24th, 2025
- After Maine native testifies before Congress, Elon Musk targets his disability - Press Herald - February 24th, 2025
- Ozempic could BLIND you - it damages veins in the eye, major study finds - Daily Mail - February 24th, 2025
- Cerebral Venous Thrombosis Presenting With Binocular Blindness and Bilateral Sensorineural Hearing Loss - Cureus - February 24th, 2025
- Treatment for horses may lead to therapy for type of blindness - Mid Florida Newspapers - February 24th, 2025
- The Murder Capital: Blindness album review - Louder Than War - February 24th, 2025
- 'First in the world': London doctors cure blindness in children born with a genetic condition - WION - February 24th, 2025
- Doctors cure rare blindness in infants with gene therapy - NewsBytes - February 24th, 2025
- Gene therapy new trial treats rare blindness in children - Daily Jang - February 24th, 2025
- Ozempic Blindness Could Be Rare but Real: What Experts Say About the Risk - ZME Science - February 24th, 2025
- Parents of boy with rare eye condition hail amazing results of gene therapy - Yahoo News UK - February 24th, 2025
- Myths and Assumptions about Blindness - BBC.com - February 24th, 2025
- Man accused of beating victim, causing permanent blindness in one eye - KAIT - February 15th, 2025
- Scientists Find Link Between Weight Loss Drugs and Blindness - AOL - February 15th, 2025
- Treatment for horses may lead to therapy for type of blindness - University of Florida - February 15th, 2025
- How Ageism Impacts Adults with Low Vision - National Council on Aging - February 15th, 2025
- Ozempic and other weight loss drugs may be linked to conditions that could lead to blindness, study says - Quartz - February 15th, 2025
- Treatment for horses may lead to therapy for type of blindness - Phys.org - February 15th, 2025
- Treatment for Horses May Lead to Therapy for Type of Blindness - Morning Ag Clips - - February 15th, 2025
- Foundation Fighting Blindness Celebrates 20 Years of VisionWalk - PR Newswire - February 15th, 2025
- Woman Victim of 'Lash Blindness'Shock at How She Looks Without Them - Newsweek - February 15th, 2025
- Some Ozempic users are losing their vision - but scientists dont know why - The Independent - February 15th, 2025
- Those with visual impairments or blindness tackling the trails at Pico Mountain - WCAX - February 15th, 2025
- Prevent Blindness Issues Call for Nominations for the 2025 Jenny Pomeroy Award for Excellence in Vision and Public Health, and Rising Visionary Award... - February 15th, 2025
- Medical warning: Ozempic and Mounjaro may be linked to vision loss - India Today - February 15th, 2025
- New research links Ozempic to vision loss and risk of blindness - MSN - February 15th, 2025
- Ozempic Blindness: Weight Loss Drugs Linked to This Condition, Experts Warn - Tech Times - February 15th, 2025
- Ozempic Blindness Lawsuit Mounts: Shocking Side Effect Of Weight Loss Drug Is 'Eye Stroke,' What You Need To Know - IBTimes UK - February 15th, 2025
- The Politics Of Erasure: Gaza, Genocide, And The Wests Wilful Blindness OpEd - Eurasia Review - February 15th, 2025
- WHO launches new initiative to tackle the main cause of vision impairment - December 19th, 2024
- Blindness Advocates on Why There Should Be Audio Description Oscars - Variety - December 19th, 2024
- Diabetic retinopathy is treatable and preventable but only if you catch it in time - USA TODAY - December 19th, 2024
- AI: Could it help prevent blindness in diabetics? - BBC.com - December 19th, 2024
- Health Officials Investigate Rare Form of Blindness Tied to Ozempic - Gizmodo - December 19th, 2024
- Ozempic Could Be Blinding People Trying to Lose Weight - VICE - December 19th, 2024
- What is retinitis pigmentosathe vision disorder in the movie Blink? - National Geographic - December 19th, 2024
- VR shows promise in aiding navigation of people with blindness or low vision - Health Tech World - December 19th, 2024
- Ozempic could be linked to a common cause of sudden blindness, study finds - Quartz - December 19th, 2024
- New virtual realitytested system shows promise in aiding navigation of people with blindness or low vision - Tech Xplore - December 19th, 2024
- Ex-meth user who gouged her own eyeballs out while high says she is happier years after nightmarish episode - New York Post - December 19th, 2024
- Officials investigating link between Ozempic and eye-rotting disease that makes people blind - Daily Mail - December 19th, 2024
- Youngster to 'have eye removed' after minor fall - but NHS waitlist 'over 3 years' - NationalWorld - December 19th, 2024
- Restoring Vision: The Promise of Stem Cells in Healing Blindness - This is Local London - December 19th, 2024
- COAVS and Fred Hollows Foundation strengthen efforts to combat blindness in Pakistan - 24newshd - December 19th, 2024
- Study finds link between Ozempic and increased risk of vision loss - The Express Tribune - December 19th, 2024
- Going blind at 33 is devastating I wont see my childrens faces as they grow up - The Telegraph - December 19th, 2024
- Europol terror report reveals stark blindness about where the danger lies - Gript - December 19th, 2024
- Elton John lost his vision; signs and symptoms of eye infections that can cause blindness - The Times of India - December 6th, 2024
- Elton John's battle with blindness: How 77-year-old star's husband David Furnish guided him around premiere as - Daily Mail - December 6th, 2024
- Experimental study shows connection between COVID infection and age-related blindness - Medical Xpress - December 6th, 2024
- Elton John confirms shocking blindness after severe infection fight: I havent been able to see.. - Hindustan Times - December 6th, 2024
- Yes, an Eye Infection *Can* Lead To Vision Loss Heres How - Katie Couric Media - December 6th, 2024
- Elton John Battling Partial Blindness After Serious Eye Infection - Digital Music News - December 6th, 2024
- CU Anschutz researchers working to cure blindness through total eye transplantation - 9News.com KUSA - December 6th, 2024
- Elton John lost his vision from an eye infection. Here's why that might happenand how to prevent it - Fortune - December 6th, 2024
- Elton John announces blindness due to infection - CBS19.tv KYTX - December 6th, 2024
- David Frost: I suffer from face blindness. As a politician, being unable to identify people is agony - The Telegraph - December 6th, 2024
- Hes still standing how Elton John has survived far worse than blindness - The Telegraph - December 6th, 2024
- Foundation Fighting Blindness Partners with University of Colorado Anschutz Medical Campus and Other Leading Institutions to Secure Up to $46 Million... - December 6th, 2024
- Walmart helping low vison and blind customers shop with new app - KSLA - December 6th, 2024
- Elton John Says He Is Blind In The Right Eye Due to An Infection; What Is It All About? - Times Now - December 6th, 2024
- Trumps Win: The Blindness of Republicans and Democrats - The Times of Israel - December 6th, 2024